XOMA Royalty Corp 13D

BVF and affiliates exited their former XOMA Royalty Corp stake via the July 14, 2026 merger with Ligand, receiving $39.00 per share plus contingent value rights and reporting no continuing activist plans.

Biotechnology Value Fund and related BVF entities filed an amended Schedule 13D on 2026-07-16 reporting that, as a result of XOMA Royalty Corp’s July 14, 2026 merger with Ligand Pharmaceuticals Incorporated, all of their XOMA shares were converted into $39.00 per share in cash plus contingent value rights, and they therefore no longer beneficially own any XOMA securities and have exited their former >5% position without stating any ongoing activist intentions.

Filing Facts

CIK

791908

Ticker

XOMA

Form

13D

Source Type

fda

Accession

0000921895-26-001822

Alert Tier

7